申请人:Daiichi Sankyo Company, Limited
公开号:EP2548872A1
公开(公告)日:2013-01-23
A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.
由以下通式(I)代表的化合物或其药理学上可接受的盐,其中 R1 代表 C1 至 C6 烷基,该烷基可被选自取代基 A 的一至三个基团或类似基团取代(取代基 A:羟基、卤代基、氰基、硝基、氨基、羧基、C1 至 C3 烷基等);R2、R3 和 R8 各自独立地代表氢原子或 C1 至 C3 烷基;R4、R5、R6、R7、R9 和 R10 各自独立地代表氢原子或 C1 至 C3 烷基。);R2、R3 和 R8 各自独立地代表氢原子或 C1 至 C3 烷基;R4、R5、R6、R7、R9 和 R10 各自独立地代表氢原子或类似物;以及 R11 代表氢原子或类似物,具有 TAFIa 酶抑制活性,可用作心肌梗塞、心绞痛、急性冠状动脉综合征、脑梗塞、深静脉血栓形成、肺栓塞或类似疾病的治疗药物。